Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

43.90 -0.15 (-0.34%)

Streaming Delayed Price Updated: 12:56 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

1 Value Stock with Exciting Potential and 2 We Avoid

August 25, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Royalty Pharma PLC - Class A (NASDAQ:RPRX) Shows Strong Technical Breakout Potential with High ChartMill Ratings ↗

August 15, 2025

Royalty Pharma (RPRX) shows strong breakout potential with high technical and setup ratings, solid trend consistency, and clear support levels. Ideal for traders eyeing momentum stocks.

Via Chartmill

1 Healthcare Stock for Long-Term Investors and 2 We Ignore

August 15, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the...

Via StockStory

Topics Stocks

Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

A Look Into Royalty Pharma Inc's Price Over Earnings ↗

June 23, 2025

Via Benzinga

How Is The Market Feeling About Royalty Pharma? ↗

June 19, 2025

Via Benzinga

RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments

August 12, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.7% year on year to $578.7 million. Its non-GAAP profit of $1.14...

Via StockStory

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)

August 10, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Royalty Pharma (RPRX) Q2 Receipts Up 20% ↗

August 06, 2025

Via The Motley Fool

Royalty Pharma PLC (NASDAQ:RPRX) Exceeds Q2 2025 Earnings Estimates and Raises Full-Year Guidance ↗

August 06, 2025

Royalty Pharma (RPRX) beats Q2 2025 earnings with $727M revenue, up 20% YoY, driven by key therapies. Shares rise as company raises full-year guidance, reinforcing growth confidence.

Via Chartmill

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates

August 06, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 7.8% year on year to $579 million. Its GAAP profit of $0.16 per...

Via StockStory

Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow

August 04, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell. Here’s what to look for.

Via StockStory

Topics Government World Trade

2 Reasons to Watch RPRX and 1 to Stay Cautious

July 30, 2025

Royalty Pharma has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $36.72, marking a 16.2% gain. This was partly thanks to its...

Via StockStory

Topics Stocks

3 Profitable Stocks to Research Further

July 28, 2025

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...

Via StockStory

Topics Supply Chain

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

July 09, 2025

Via Benzinga

2 Surging Stocks to Research Further and 1 to Be Wary Of

June 26, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Via StockStory

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds ↗

June 24, 2025

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Via Benzinga

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma ↗

June 24, 2025

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured...

Via Stocktwits

Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks

June 18, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives

June 09, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $568.2 million. Its non-GAAP EPS of $1.06 per share was...

Via StockStory

2 Value Stocks to Target This Week and 1 to Turn Down

June 06, 2025

Via StockStory

1 Stock Under $50 with Competitive Advantages and 2 to Question

June 04, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 23, 2025

Via Benzinga

3 of Wall Street’s Favorite Stocks with Mounting Challenges

May 15, 2025

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional...

Via StockStory

Royalty Pharma (NASDAQ:RPRX) Posts Q1 Sales In Line With Estimates

May 08, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $568 million. Its GAAP profit of $0.75 per share...

Via StockStory

Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings

May 07, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results tomorrow before the bell. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors ↗

May 01, 2025

Royalty Pharma PLC - CL A (NASDAQ:RPRX) Shows Strong Technical Setup for Breakout Investors

Via Chartmill

ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) Technical Analysis observations. ↗

May 01, 2025

Exploring ROYALTY PHARMA PLC- CL A's Technical Signals and Breakout Potential: Indications Suggest NASDAQ:RPRX Could Be on the Verge of a Breakout.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.